EGFR and non-small cell lung carcinoma: A common approach for treating oligoprogression in EGFR-mutant advanced NSCLC patients is to continue the EGFR-TKI that is controlling the greater proportion of the disease, while using local ablative therapy to eradicate the resistant clones in the area or areas of progression.